| Literature DB >> 26445269 |
Bruno Neuner1, Anna Lenfers2, Reinhard Kelsch3, Kathrin Jäger4, Nina Brüggmann5, Pim van der Harst6, Michael Walter4.
Abstract
Telomere length (TL) is considered a marker of biological aging and has been associated with the presence of various coronary risk factors in patients. Much less is known about the relationships between TL and classic coronary risk factors in other populations. We measured TL in peripheral blood leukocytes of 343 middle-aged blood donors (mean age 40.2 ± 12.4 years; 201 men, 142 women) using quantitative polymerase chain reaction. Median TL was 0.86 (range: 0.48-1.85) relative TL units. In linear regression analyses with natural log-transformed T to S ratio as the dependent variable, there was a significant association with age (per year: beta = -0.007, p<0.001) and sex (males vs. females: beta = 0.075, p = 0.007) with longer telomeres in men. After adjusting for these two variables, we observed no association of TL with classic coronary risk factors including cholesterol (p = 0.36), triglyceride (p = 0.09), HDL-cholesterol (p = 0.26), LDL-cholesterol (p = 0.36), smoking (p = 0.97), and personal (p = 0.46) or family history (p = 0.63) of cardiovascular disease. However, we did find a significant positive association with white (p = 0.011) and red blood cell count (p = 0.031), hemoglobin (p = 0.014) and hematocrit (p = 0.013); we also found a borderline positive association with thrombocytes (p = 0.074). Positive associations remained significant for hemoglobin (p = 0.017), hematocrit (p = 0.023), and leukocytes (p = 0.009) in a subgroup with no reported vascular disease; associations were of borderline significance for erythrocytes (p = 0.053) and thrombocytes (p = 0.088) in this subgroup. The data do not support the concept that classic coronary risk factors contribute to telomere attrition in a blood donor population. However, telomere attrition may be a marker for reduced proliferation reserve in hematopoietic progenitor cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26445269 PMCID: PMC4596489 DOI: 10.1371/journal.pone.0139308
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Telomere length (untransformed) in all patients, n = 343 (A); Telomere length (natural log-transformed) in all patients, n = 343 (B).
T/S was non-normally distributed (A). A natural log-transformation was performed to obtain a near-normal distribution (B).
Telomere length and baseline characteristics in all patients and stratified by gender, n = 343.
| Parameter | Total(N = 343) | Men(N = 201) | Women(N = 142) | p Value |
|---|---|---|---|---|
| Age in years (min–max) | 40.2 ± 12.4(18–71) | 39.3 ± 11.7(18–71) | 41.6 ± 13.3(19–70) | 0.10 |
| T to S ratio (qPCR), untransformed | 0.86 (0.48–1.85) | 0.88 (0.49–1.85) | 0.81 (0.48–1.64) | 0.007 MWU-test |
| T to S ratio (qPCR), natural log-transformed | -0.14 ± 0.25 | -0.11 ± 0.26 | -0.18 ± 0.24 | 0.007 |
| Smoking, n (%) (n = 342) | 76 (22.%) | 52 (26.0%) | 24 (16.9%) | 0.046 |
| Pack-years in smokers (n = 76) | 12.0 ± 9.5 | 12.6 ± 9.4 | 10.7 ± 9.9 | 0.42 |
| Body mass index, kg m−2 (n = 340) | 24.5 (18.4–41.4) | 25.1 (19.2–31.9) | 23.5 (18.4–41.4) | < 0.001 MWU-test |
| Obesity (BMI > 30 kg m−2), n (%) (n = 340) | 33 (9.7%) | 20 (10.1%) | 13 (9.2%) | 0.77 |
| Glucose, mmol/L (n = 338) | 82 (37–332) | 84 (37–332) | 80 (39–200) | 0.15 MWU-test |
| Hypertension, n (%) | 4 (1.2%) | 1 (0.5%) | 3 (2.1%) | 0.31 |
| Systolic blood pressure, mmHg | 125.0 ± 9.0 | 126.8 ± 9.4 | 122.4 ± 7.6 | <0.001 |
| Diastolic blood pressure, mmHg | 79.3 ± 4.8 | 80.2 ± 4.4 | 78.1 ± 5.0 | <0.001 |
| Cholesterol, mmol/L (n = 338) | 196 ± 38 | 194 ± 35 | 200 ± 41 | 0.18 |
| LDL cholesterol, mmol/L (n = 339) | 114 ± 32 | 115 ± 32 | 113 ± 32 | 0.56 |
| Hypercholesterolemia (LDL > 130 mmol/L), n (%) (n = 339) | 96 (2.38%) | 65 (32.5%) | 31 (22.3%) | 0.040 |
| HDL cholesterol, mmol/L(n = 339) | 57 ± 15 | 52 ± 12 | 64 ± 16 | <0.001 |
| Triglycerides, mmol/L (n = 338) | 115 (10–432) | 121 (10–432) | 106 (36–370) | 0.006 MWU-test |
| Triglycerides > 150 mmol/L + HDL < 50 mmol/L (♀) resp. < 40 mmol/L (♂), n (%) (n = 338) | 35 (10.4%) | 21 (10.6%) | 14 (10.1%) | 0.89 |
| Metabolic Syndrome | 94 (27.7%) | 49 (24.5%) | 45 (32.4%) | 0.11 |
| Fibrinogen, μmol/L (n = 333) | 269 (80–694) | 260.5 (97–578) | 299 (80–694) | < 0.001 MWU-test |
| Hyperfibrinogenemia (fibrinogen > 350 μmol/L), n (%) (n = 333) | 52 (15.6%) | 18 (9.2%) | 34 (24.8%) | < 0.001 |
| Creatinine, μmol/L | 0.87 ± 0.16 | 0.94 ± 0.13 | 0.76 ± 0.12 | < 0.001 |
| GOT, U/L (n = 338) | 24 (14–148) | 26 (16–137) | 22 (14–148) | < 0.001 MWU-test |
| GPT, U/L (n = 338) | 18 (2–266) | 21 (2–150) | 14 (4–266) | <0.001 MWU-test |
| Hemoglobin, g/dL (n = 317) | 14.2 ± 1.3 | 14.9 ± 1.1 | 13.3 ± 0.9 | <0.001 |
| Hematocrit, % (n = 316) | 40.4 ± 3.2 | 41.9 ± 2.9 | 38.3 ± 2.4 | <0.001 |
| Erythrocytes, 1012/L (n = 316) | 4.6 ± 0.4 | 4.8 ± 0.4 | 4.4 ± 0.3 | <0.001 |
| MCV, 10−15 L (n = 317) | 87.0 ± 4.0 | 87.0 ± 3.9 | 87.1 ± 4.1 | 0.87 |
| MCH, pg (n = 316) | 30.8 (2.5–35.1) | 31.1 (24.9–35.1) | 30.4 (2.5–34.2) | 0.002 MWU-test |
| MCHC, g/dL (n = 317) | 35.2 (30.8–345.6) | 35.6 (32.9–345.6) | 35.0 (30.8–36.8) | <0.001 MWU-test |
| Leukocytes, 109/L (n = 317) | 5.7 ± 1.4 | 5.5 ± 1.2 | 5.9 ± 1.5 | 0.051 |
| Thrombocytes, 109/L (n = 317) | 243.1 ± 57.1 | 228.9 ± 50.1 | 263.0.0 ± 60.4 | <0.001 |
| Vascular disease, % | 19 (5.5%) | 4 (2.0%) | 15 (10.6) | 0.001 |
| Positive family history of vascular disease, n (%) (n = 342) | 118 (34.5%) | 54 (27.0%) | 64 (45.1%) | 0.001 |
Count data presented as n(%) and continuous data given as mean ± SD or median (range), respectively
# independent-samples t test respectively Mann-Whitney-U-Test (MWU-test) or the χ2 test
† one outlier removed
$ = Fisher’s Exact Test
BMI = Body mass index
LDL = low density lipoprotein
HDL = high density lipoprotein
GOT = Glutamat-Oxalacetat-Transaminase
GPT = Glutamat-Pyruvat-Transaminase
MCV = Mean corpuscular volume
MCH = Mean corpuscular hemoglobin
MCHC = Mean corpuscular hemoglobin concentration
# = Hyperfibrinogenemia and/or obesity and/or triglycerides > 150 mmol/L combined with HDL < 50 mmol/L (♀) resp. < 40 mmol/L (♂).
Influence of risk factors on telomere length (natural log-transformed T/S ratio), results of linear regression models, n = 343.
| Independent parameters | unadjusted | adjusted | ||||
|---|---|---|---|---|---|---|
| betax | 95%-CI | p-value | betax | 95%-CI | p-value | |
| Age, per year | -0.007 | -0.009 to -0.005 | < 0.001 | - | - | - |
| Male vs. female gender | 0.075 | 0.021 to 0.129 | 0.007 | - | - | - |
| Smoking, yes vs. no | 0.027 | -0.038 to 0.092 | 0.41 | 0.001 | -0.060 to 0.062 | 0.97 |
| Pack-years, per year (in smokers) | 0.008 | -0.021 to 0.037 | 0.53 | -0.003 | -0.030 to 0.025 | 0.85 |
| Body mass index, per unit (kg/m2) | -0.007 | -0.014 to 0.000 | 0.05 | -0.004 | -0.011 to 0.003 | 0.23 |
| Obesity (BMI > 30 kg m−2), yes vs. no | -0.024 | -0.115 to 0.067 | 0.60 | -0.009 | -0.094 to 0.076 | 0.84 |
| Glucose, per 10 mmol/L | -0.012 | -0.023 to -0.001 | 0.033 | -0.005 | -0.016 to 0.006 | 0.36 |
| Systolic blood pressure, per 10 mmHg | 0.002 | -0.028 to 0.032 | 0.92 | 0.003 | -0.026 to 0.033 | 0.82 |
| Diastolic blood pressure, per 10 mmHg | -0.028 | -0.084 to 0.028 | 0.33 | -0.022 | -0.076 to 0.033 | 0.43 |
| Cholesterol, per 10 mmol/L | -0.014 | -0.021 to– 0.007 | < 0.001 | -0.004 | -0.011 to 0.004 | 0.36 |
| LDL cholesterol, per 10 mmol/L | -0.015 | - 0.023 to -0.006 | 0.001 | -0.004 | -0.013 to 0.005 | 0.36 |
| Hypercholesterolemia (LDL > 130 mmol/L), yes vs. no | -0.071 | -0.130 to -0.011 | 0.020 | -0.015 | -0.075 to 0.045 | 0.62 |
| HDL cholesterol, per 10 mmol/L | -0.017 | -0.034 to 0.001 | 0.065 | -0.010 | -0.028 to 0.008 | 0.26 |
| Triglycerides, per 10 mmol/L | 0.002 | -0.002 to 0.005 | 0.44 | 0.003 | 0.000 to 0.007 | 0.086 |
| Triglycerides > 150 mmol/L + HDL < 50 mmol/L (♀) resp. < 40 mmol/L (♂), yes vs. no | 0.020 | -0.070 to 0.109 | 0.67 | 0.038 | -0.045 to 0.121 | 0.37 |
| Metabolic Syndrome | -0.048 | -0.108 to 0.012 | 0.12 | 0.012 | -0.046 to 0.071 | 0.68 |
| Fibrinogen, per 10 μmol/L | -0.005 | -0.009 to– 0.002 | 0.002 | -0.002 | -0.006 to 0.001 | 0.22 |
| Hyperfibrinogenemia (fibrinogen > 350 μmol/L), yes vs. no | -0.064 | -0.138 to 0.010 | 0.09 | 0.014 | -0.060 to 0.088 | 0.72 |
| Creatinine, per 10 μmol/L | 0.012 | -0.212 to 0.236 | 0.92 | -0.024 | -0.234 to 0.186 | 0.82 |
| GOT, per 10 U/L | -0.001 | -0.026 to 0.024 | 0.94 | -0.009 | -0.033 to 0.014 | 0.44 |
| GPT, per 10 U/L | -0.011 | -0.025 to 0.003 | 0.13 | -0.014 | -0.028 to -0.001 |
|
| Hemoglobin per 10 g/dL | 0.378 | 0.161 to 0.595 | 0.001 | 0.322 | 0.067 to 0.577 |
|
| Hematocrit, per % | 0.015 | 0.006 to 0.024 | 0.001 | 0.012 | 0.003 to 0.022 |
|
| Erythrocytes, per 1012/L | 0.128 | 0.063 to 0.193 | < 0.001 | 0.078 | 0.007 to 0.149 |
|
| MCV, per 10 fL | -0.058 | -0.129 to 0.013 | 0.11 | 0.005 | -0.064 to 0.073 | 0.89 |
| MCH, per 10 pg | -0.033 | -0.151 to 0.085 | 0.58 | 0.029 | -0.085 to 0.143 | 0.62 |
| MCHC, per 10 g/dL | 0.004 | -0.012 to 0.020 | 0.64 | -0.001 | -0.016 to 0.015 | 0.95 |
| Leukocytes, per 109/L | 0.013 | -0.007 to 0.034 | 0.21 | 0.025 | 0.006 to 0.044 |
|
| Thrombocytes, per 1012/L | 0.177 | -0.317 to 0.672 | 0.48 | 0.436 | -0.043 to 0.914 | 0.074 |
| Vascular disease, yes vs. no | -0.136 | -0.253 to -0.019 | 0.023 | -0.043 | -0.156 to 0.071 | 0.46 |
| Positive family history of vascular disease, yes vs. no | -0.059 | -0.115 to -0.003 | 0.041 | 0.014 | -0.043 to 0.071 | 0.63 |
#: adjustments for age and sex
CI = confidence interval
† = one outlier removed before regression analyses
BMI = Body mass index
LDL = low density lipoprotein
HDL = high density lipoprotein
GOT = Glutamat-Oxalacetat-Transaminase
GPT = Glutamat-Pyruvat-Transaminase
MCV = Mean corpuscular volume
MCH = Mean corpuscular hemoglobin
MCHC = Mean corpuscular hemoglobin concentration
## = Hyperfibrinogenemia and/or obesity and/or triglycerides > 150 mmol/L combined with HDL < 50 mmol/L (♀) resp. < 40 mmol/L (♂).
Fig 2Age and natural log-transformed telomere length, males and females, n = 343.
The association of TL with age, visualized by the regression lines for men (blue circles) and women (green circles), respectively.
Influence of risk factors on telomere length (natural log-transformed T/S ratio), results of linear regression models in patients without vascular disease, n = 324.
| Independent parameters | unadjusted | adjusted | ||||
|---|---|---|---|---|---|---|
| betax | 95%-CI | p-value | betax | 95%-CI | p-value | |
| Age, per year | -0.007 | -0.009 to -0.004 | < 0.001 | - | - | - |
| Male vs. female gender | 0.064 | 0.008 to 0.120 | 0.003 | - | - | - |
| Smoking, yes vs. no | 0.020 | -0,046 to 0.085 | 0.56 | -0.003 | -0.065 to 0.060 | 0.94 |
| Pack-years, per year (in smokers) | 0.007 | -0.022 to 0.036 | 0.63 | -0.002 | -0.030 to 0.025 | 0.86 |
| Body mass index, per unit (kg/m2) | 0.006 | -0.013 to 0.001 | 0.11 | -0.004 | -0.011 to 0.003 | 0.28 |
| Obesity (BMI > 30 kg m−2), yes vs. no | 0.004 | -0.093 to 0.102 | 0.93 | 0.007 | -0.085 to 0.099 | 0.88 |
| Glucose, per 10 mmol/L | -0.012 | -0.024 to -0.001 | 0.033 | -0.005 | -0.017 to 0.006 | 0.34 |
| Systolic blood pressure, per 10 mmHg | 0.003 | -0.028 to 0.033 | 0.86 | 0.004 | -0.025 to 0.034 | 0.77 |
| Diastolic blood pressure, per 10 mmHg | -0.021 | -0.079 to 0.038 | 0.49 | -0.014 | -0.071 to 0.043 | 0.64 |
| Cholesterol, per 10 mmol/L | -0.012 | -0.020 to– 0.005 | 0.001 | -0.003 | -0.011 to 0.005 | 0.49 |
| LDL cholesterol, per 10 mmol/L | -0.012 | - 0.021 to -0.004 | 0.006 | -0.002 | -0.012 to 0.007 | 0.60 |
| Hypercholesterolemia (LDL > 130 mmol/L), yes vs. no | -0.056 | -0.117 to 0.006 | 0.078 | -0.005 | -0.067 to 0.058 | 0.88 |
| HDL cholesterol, per 10 mmol/L | -0.019 | -0.037 to -0.001 | 0.044 | -0.013 | -0.032 to 0.006 | 0.17 |
| Triglycerides, per 10 mmol/L | 0.002 | -0.002 to 0.006 | 0.37 | 0.003 | -0.001 to 0.007 | 0.090 |
| Triglycerides > 150 mmol/L + HDL < 50 mmol/L (♀) resp. < 40 mmol/L (♂), yes vs. no | 0.048 | -0.046 to 0.142 | 0.31 | 0.062 | -0.026 to 0.151 | 0.17 |
| Metabolic Syndrome | -0.029 | -0.092 to 0.034 | 0.37 | 0.024 | -0.037 to 0.085 | 0.44 |
| Fibrinogen, per 10 μmol/L | -0.005 | -0.008 to– 0.001 | 0.007 | -0.002 | -0.005 to 0.002 | 0.38 |
| Hyperfibrinogenemia (fibrinogen > 350 μmol/L), yes vs. no | -0.056 | -0.133 to 0.021 | 0.16 | 0.018 | -0.060 to 0.095 | 0.65 |
| Creatinine, per 10 μmol/L | -0.001 | -0.224 to 0.223 | 0.99 | -0.027 | -0.239 to 0.185 | 0.80 |
| GOT, per 10 U/L | -0.002 | -0.027 to 0.024 | 0.90 | -0.009 | -0.033 to 0.016 | 0.49 |
| GPT, per 10 U/L | -0.010 | -0.025 to 0.005 | 0.20 | -0.013 | -0.028 to 0.001 | 0.076 |
| Hemoglobin, per 10 g/dL | 0.345 | 0.124 to 0.566 | 0.002 | 0.320 | 0.057 to 0.584 |
|
| Hematocrit, per % | 0.014 | 0.005 to 0.023 | 0.003 | 0.012 | 0.002 to 0.022 |
|
| Erythrocytes, per 1012/L | 0.114 | 0.048 to 0.181 | 0.001 | 0.072 | -0.001 to 0.146 | 0.053 |
| MCV, per 10 fL | -0.048 | -0.121 to 0.024 | 0.19 | 0.007 | -0.064 to 0.078 | 0.84 |
| MCH, per 10 pg | -0.020 | -0.139 to 0.098 | 0.74 | 0.037 | -0.079 to 0.153 | 0.53 |
| MCHC, per 10 g/dL | 0.004 | -0.013 to 0.020 | 0.67 | 0.000 | -0.015 to 0.015 | 0.97 |
| Leukocytes, per 109/L | 0.015 | -0.006 to 0.036 | 0.17 | 0.027 | 0.007 to 0.047 |
|
| Thrombocytes, per 1012/L | 0.237 | -0.272 to 0.745 | 0.36 | 0.432 | -0.065 to 0.930 | 0.088 |
| Positive family history of vascular disease, yes vs. no | -0.038 | -0.097 to -0.021 | 0.21 | 0.022 | -0.037 to 0.081 | 0.46 |
#: adjustments for age and sex
CI = confidence interval
† = one outlier removed before regression analyses
BMI = Body mass index
LDL = low density lipoprotein
HDL = high density lipoprotein
GOT = Glutamat-Oxalacetat-Transaminase
GPT = Glutamat-Pyruvat-Transaminase
MCV = Mean corpuscular volume
MCH = Mean corpuscular hemoglobin
MCHC = Mean corpuscular hemoglobin concentration
## = Hyperfibrinogenemia and/or obesity and/or triglycerides > 150 mmol/L combined with HDL < 50 mmol/L (♀) resp. < 40 mmol/L (♂).